2406-2407 / 2953
CHHiP Study
3216 men randomised
Risk group 15% low, 73% intermediate, 12% high.
Median duration of hormone therapy was 5.6m.
Median follow up of 62.3m
5yr progression-free rate
74Gy: 88.3% (86.0%, 90.2%)
60Gy: 90.6% (88.5%, 92.3%)
57Gy: 85.9%(83.4%, 88.0%)